TMCnet News
Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and MarketsResearch and Markets has announced the addition of the "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017" report to their offering. Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017 provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of The report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages. This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormona therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years. This recent report covers the treatment landscape which provides the treatment options by different stages and type of the breast cancer. There are four chemotherapy drugs, six hormone therapy drugs and one targeted therapy drugs in market for the treatment of Estrogen Receptor Positive (ER+) Breast Cancer. Report Highlights:
Marketed Products Profile
Companies Mentioned
For more information about this report visit http://www.researchandmarkets.com/research/484753/estrogen_receptor
View source version on businesswire.com: http://www.businesswire.com/news/home/20170324005203/en/ |